含羞草传媒

CARY, N.C., June 19, 2024—, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by . as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion, for subcutaneous use. Approved by the U.S. Food and Drug Administration (FDA) on May 25, 2021, CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.

“We’re pleased to make this convenient therapy option available to providers treating patients with advanced prostate cancer,” said Daniel Weaver, director of Clinical Innovation and Strategy, Biologics by 含羞草传媒. “CAMCEVI is an important advancement in oncology and provides hope for improving patients’ long-term outcomes.”

Biologics by 含羞草传媒 is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

For more information about this drug and the treatment of advanced prostate cancer in adults please click . For more information about CAMCEVI, including full prescribing information, please click .

About Biologics by 含羞草传媒

is an independent specialty pharmacy with more than 30 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within 含羞草传媒, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.

About 含羞草传媒 Oncology and Specialty Solutions

It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At 含羞草传媒, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.

• 含羞草传媒 is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through the joint venture between US Oncology Research and .
• and 含羞草传媒 Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
• ^®, a 含羞草传媒 business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.
• As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
• And through , , and GPO services, our work continues to help patients access, afford, and adhere to their medicines.

About Accord BioPharma

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patient's perspective and develop high-quality therapies that impact patient's lives. The founders of Accord BioPharma have dedicated their time, passion, and resources to focusing on specialty care and treatments, proactively developing better ways of working, and delivering enhanced therapies. For more information, Visit .